Hyperbaric oxygen therapy (HBOT) has moved from the hospital wound-care unit into the wellness clinic, the med-spa, and the longevity programme. Once reserved for decompression sickness and diabetic foot ulcers, HBOT is now increasingly used as an adjunctive intervention for skin health, scar management, and aesthetic recovery. The question for anyone considering it is straightforward: does the evidence justify the time, cost, and commitment—and at what pressure?
What HBOT Does to Skin at the Cellular Level
The core principle is simple. At normal atmospheric pressure (1 ATA), oxygen is carried almost entirely by hemoglobin. Breathing 100% oxygen at sea level adds little to the oxygen already in the bloodstream. But when pressure increases, oxygen dissolves directly into blood plasma in quantities that hemoglobin transport cannot match. This dissolved oxygen reaches tissues independently of red blood cell delivery, penetrating ischemic and inflamed areas that are poorly served by normal circulation-14.
In skin, three downstream effects matter most.
Collagen synthesis. Fibroblast proliferation and collagen matrix deposition depend on oxygen-dependent hydroxylation enzymes—prolyl and lysyl hydroxylase. Without adequate oxygen, collagen production stalls. Elevated plasma oxygen accelerates these enzymatic reactions, supporting tensile strength in healing incisions and improving the structural integrity of aged skin-14.
Angiogenesis. Hyperoxia upregulates vascular endothelial growth factor (VEGF), triggering the formation of new capillary networks in healing tissue beds-14. Geram Health, a manufacturer of hyperbaric chambers, summaries the mechanism clearly: HBOT encourages the formation of new collagen and new skin cells by stimulating new blood vessel growth and by prompting cells to produce substances such as VEGF, which attract and activate the endothelial cells needed for healing-31.
Senescent cell clearance. A prospective clinical trial published in 2021 provided the first human evidence that HBOT can modulate the pathophysiology of skin ageing. Following a three-month protocol, skin biopsies from participants (mean age 68.1) showed a significant increase in collagen density (p<0.001, effect size 1.10), a significant increase in elastic fibre length (p<0.0001, effect size 2.71), a significant increase in the number of blood vessels (p=0.02, effect size 1.00), and a significant decrease in tissue senescent cells (p=0.03, effect size 0.84)-44. The demonstrated mechanisms were angiogenesis and senescent cell clearance—two of the recognised hallmarks of biological ageing-44.
1.5 ATA: The Skin Healing Pressure
At 1.5 atmospheres absolute, pressure is increased by 50% above sea level. Henry’s Law dictates that gas dissolution in liquids increases proportionally, supersaturating plasma with dissolved oxygen and allowing oxygen to diffuse up to four times further into ischaemic or traumatised tissue than under normal conditions-14.
This pressure level is most commonly used for post-surgical recovery and tissue repair rather than for longevity protocols. The biological rationale is specific: fibroblast proliferation, collagen synthesis, and angiogenesis all stall under hypoxic conditions, and 1.5 ATA protocols are designed to restore oxygen tension to levels that support these processes-14. Typical clinical application involves 60- to 90-minute sessions administered daily or five days per week over a course of 20 to 40 treatments, depending on the complexity of the surgical intervention-14.
For skin specifically, 1.5 ATA is often used prophylactically before procedures such as abdominoplasty. In one study cited in an evidence-based review published in the Journal of Cosmetic Dermatology, preoperative HBOT reduced complications from 32.6% (89 patients) to 8.4% (7 patients), with a p-value below 0.001-2. The review also reported that following HBOT, there was a significant increase in elastic fibre length (p≤0.0001) and collagen fibre density (p=0.0001), alongside a significant decrease in fibre fragmentation (p=0.012)-2. These are structural changes in skin architecture, not merely subjective improvements in appearance.
Geram Health notes that its chambers are designed to accommodate pressures including 1.3 ATA, 1.5 ATA, and 2.0 ATA, reflecting the reality that different clinical and wellness objectives call for different protocols-. At 1.5 ATA, the emphasis is on recovery and repair; at higher pressures, the focus shifts toward broader systemic and anti-ageing effects.
2.0 ATA: The Longevity and Skin Radiance Pressure
At 2.0 atmospheres absolute, the dissolved oxygen content of plasma rises further. This pressure is commonly used in longevity-focused HBOT programmes, where chambers are typically smaller, designed for single or dual occupancy, and operated at exactly 2.0 ATA-21.
The scientific literature supporting 2.0 ATA for skin and systemic ageing is more developed than for lower pressures. A study at the Shai Efrati and Sagol Center demonstrated more than 20% telomere lengthening and a 10–37% reduction in senescent immune cells following 60 HBOT sessions over approximately 90 days at 2.0 ATA, with 90-minute sessions breathing 100% oxygen with intermittent breaks-21. The same protocol has been reported to produce marked improvements in whole-body skin health-21.
Longevity-focused clinicians generally regard 60 sessions as the gold-standard anti-ageing protocol. However, 20 to 40 sessions delivered three to five times per week at 2.0 ATA may provide partial benefits when completing a full course is not feasible-21. For skin specifically, 2.0 ATA protocols are associated with increased collagen production, improved skin elasticity, and enhanced tissue oxygenation-. The mechanism is consistent with the 1.5 ATA pathway—collagen synthesis, angiogenesis, and senescent cell clearance—but the higher pressure appears to engage systemic ageing biomarkers more effectively.
HBOT for Scar Management and Fibrotic Skin Conditions
Beyond cosmetic skin quality, HBOT has a well-documented role in scar management. In keloid treatment, adjunctive HBOT has been shown to reduce recurrence rates after surgical excision and radiotherapy by improving tissue oxygen levels and alleviating the inflammatory process-. Research on keloid fibroblasts found decreased fibroblast growth and reduced expression of insulin-like growth factor and transforming growth factor-beta messengers after chronic hyperbaric oxygenation-. This suggests that HBOT may modulate the fibrotic signalling that drives excessive scarring.
For systemic sclerosis and scleroderma-related skin ulcers, case reports and small series have documented pain relief and complete healing of ulcers following HBOT protocols typically administered daily over 20 to 40 sessions-. A systematic review of HBOT for pyoderma gangrenosum reported that among 48 patients treated, 58.4% experienced complete lesion healing and 20.8% showed lesion improvement-.
These are not aesthetic indications, but they illustrate the same underlying principle: skin that is chronically hypoxic and inflamed does not heal well, and restoring oxygen delivery can break that cycle.
What HBOT Does Not Do
The evidence-based review published in the Journal of Cosmetic Dermatology is candid about the limitations. The review included 17 human studies with 766 participants, and all included studies were judged to be at high risk of bias. Only three studies were classified as level II evidence-2. The authors note that current formal indications for HBOT do not encompass aesthetic applications, even as many centres promote it for skin rejuvenation-2.
In other words, the biological mechanisms are plausible and the early human data are promising, but the evidence base for aesthetic HBOT remains preliminary. This is not a reason to dismiss the therapy—it is a reason to approach marketing claims with appropriate scepticism and to prioritise protocols that have at least some clinical trial support.
Practical Considerations
HBOT for skin benefits is not a single-session intervention. The protocols that have demonstrated measurable changes in skin biopsies involved daily sessions over three months-44. Lower-pressure protocols for post-surgical recovery typically run 20 to 40 sessions-14. This means the therapy is time-consuming and expensive, and the commitment should be weighed against realistic expectations.
Geram Health, which manufactures both hard-shell and soft-shell hyperbaric chambers for clinical and wellness use, emphasizes that chamber selection should match the intended application and treatment pressure-. A soft-shell chamber operating at 1.3 ATA is not equivalent to a hard-shell chamber at 2.0 ATA, and the clinical evidence for skin benefits is strongest at the higher pressures used in the longevity and wound-care literature.
For anyone considering HBOT for skin health, the most defensible position based on current evidence is this: HBOT at 1.5 ATA is a reasonable adjunct for post-surgical skin recovery and wound healing; HBOT at 2.0 ATA has emerging evidence for modulating skin ageing at the cellular level; and neither is a substitute for standard dermatological care or a proven alternative to established aesthetic treatments.
References
1. Ben Ner D, D’Souza AR. The Role of Hyperbaric Oxygen Therapy in Enhancing Skin Regeneration and Aesthetic Outcomes: A Literature Review. Facial Plastic Surgery. 2026.
2. Parnis J, Fenech Magrin AM, Hassan H. The role, safety, and efficacy of hyperbaric oxygen therapy in aesthetic practice—An evidence-based review. Journal of Cosmetic Dermatology.
3. Geram Health. How does HBOT work?
4. Geram Health. Explanation of hyperbaric oxygen therapy pressures: applications of 1.3 ATA, 1.5 ATA, and 2.0 ATA.
5. Formula Health. Optimising Recovery and Longevity: The Science Behind 1.5 ATA Hyperbaric Oxygen Therapy Protocols. 2026.
6. Trodd T. Hyperbaric Oxygen Therapy (HBOT) as Part of a Healthspan and Longevity Programme. OT&P. 2026.
7. Makrantonaki E, et al. The effect of hyperbaric oxygen therapy on the pathophysiology of skin aging: a prospective clinical trial. Aging. 2021.
8. Hyperbaric oxygen therapy for scleroderma wounds: a report on two cases and literature review. Annals of Internal Medicine: Clinical Cases. 2025.
